Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pirfenidone in CADM-associated progressive ILD
NCT02821689Phase 4Unknown
- Sponsor
- Renji Hospital
- Start
- Jul 2016
- Primary completion
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of pirfenidone in interstitial lung disease (ILD), sponsored by Renji Hospital. Status: unknown.
02
Drugs
pirfenidone
03
Conditions
interstitial lung disease (ILD)
Beyond the preview
Go deeper on NCT02821689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02821689.